The issues European production partners (one in Belgium I think) are suffering with the AstraZeneca vaccine are similar to those already solved at the UK production sites months ago because of the risk taken to start production early.
Each production facility can have unique issues that effect yield that simply need time to resolve.
Maybe AstraZeneca over promised, but it feels like risks to production yield were not properly assessed by those in charge of ensuring vaccine supply in the EU.